{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:28:31Z","timestamp":1787056111239,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T07:11:33Z","timestamp":1697526693000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations"],"prefix":"10.1016","volume":"268","author":[{"given":"H\u00e9l\u00e8ne","family":"Verdoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9lia","family":"Quiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.10.003_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0924-977X(97)00093-X","article-title":"Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial","volume":"8","author":"Anghelescu","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2019.05.033","article-title":"Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations","volume":"210","author":"Augustin","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2165\/00003088-199631060-00004","article-title":"Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors","volume":"31","author":"Baumann","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2023.10.003_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"key":"10.1016\/j.schres.2023.10.003_bb0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5498\/wjp.v11.i7.316","article-title":"Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: a controversial but promising approach","volume":"11","author":"Bellon","year":"2021","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0030","article-title":"Interest of fluvoxamine as an add-on to clozapine in children with severe psychiatric disorder according to CYP polymorphisms: experience from a case series","volume":"12","author":"Berel","year":"2021","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2023.10.003_bb0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/cap.2021.0048","article-title":"Letter to the editor: rapid clozapine concentration increase following augmentation with low-dose fluvoxamine in 12-year-old with childhood onset schizophrenia","volume":"31","author":"Boyle","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0924-977X(01)00101-8","article-title":"Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram","volume":"11","author":"Br\u00f8sen","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/JCP.0000000000001242","article-title":"Vortioxetine on cognition in schizophrenia: a pilot study","volume":"40","author":"Bruno","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0050","first-page":"1274","article-title":"Addition of fluoxetine to clozapine","volume":"149","author":"Cassady","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0055","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1176\/ajp.153.6.820","article-title":"Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors","volume":"153","author":"Centorrino","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2022.02.035","article-title":"Amitriptyline for clozapine-induced hypersalivation: a case series","volume":"243","author":"Cereda","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000924","article-title":"Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice? My failure to convince clinicians","volume":"39","author":"de Leon","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2023.10.003_bb0080","article-title":"Clozapine is strongly associated with the risk of pneumonia and inflammation","volume":"33","author":"de Leon","year":"2020","journal-title":"Gen. Psychiatr."},{"key":"10.1016\/j.schres.2023.10.003_bb0085","article-title":"An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine","volume":"35","author":"de Leon","year":"2022","journal-title":"Gen. Psychiatr."},{"key":"10.1016\/j.schres.2023.10.003_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/070674370404900719","article-title":"Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief treatment with dantrolene","volume":"49","author":"Ferioli","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0100","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1520\/JFS14363J","article-title":"A fatal drug interaction between clozapine and fluoxetine","volume":"43","author":"Ferslew","year":"1998","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.schres.2023.10.003_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1065","article-title":"Lower sertraline plasma concentration in patients co-medicated with clozapine-implications for pharmacological augmentation strategies in schizophrenia","volume":"11","author":"Gaebler","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.schres.2023.10.003_bb0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/acps.12854","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.10.003_bb0115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF03324659","article-title":"Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine","volume":"18","author":"Gambassi","year":"2006","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1345\/aph.19368","article-title":"Neuroleptic malignant syndrome with antidepressant\/antipsychotic drug combination","volume":"35","author":"Garcia","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2023.10.003_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.v59n0107d","article-title":"Leukopenia associated with addition of paroxetine to clozapine","volume":"59","author":"George","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0130","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1345\/aph.16185a","article-title":"Comment: sudden cardiac death with clozapine and sertraline combination","volume":"35","author":"Gillespie","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2023.10.003_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/neu.2022.30","article-title":"Augmentation strategies for clozapine resistance: a systematic review and meta-analysis","volume":"35","author":"Grover","year":"2023","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.schres.2023.10.003_bb0140","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","article-title":"Elevated levels of clozapine in serum after addition of fluvoxamine","volume":"14","author":"Hiemke","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2012.01.008","article-title":"Antidepressant prescribing patterns among VA patients with schizophrenia","volume":"136","author":"Himelhoch","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002139900351","article-title":"Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight","volume":"149","author":"Hinze-Selch","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2023.10.003_bb0160","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1345\/aph.16185","article-title":"Sudden cardiac death with clozapine and sertraline combination","volume":"35","author":"Hoehns","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2023.10.003_bb0165","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/02698811211003477","article-title":"Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age","volume":"35","author":"Hommers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0170","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.10.003_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000505876","article-title":"Clozapine-associated obsessive-compulsive symptoms and their management: a systematic review and analysis of 107 reported cases","volume":"89","author":"Kim","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2023.10.003_bb0180","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/JCP.0000000000001605","article-title":"Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses","volume":"42","author":"Kim","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.13421","article-title":"Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers","volume":"127","author":"Kuzin","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.schres.2023.10.003_bb0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/JCP.0000000000001342","article-title":"High-dose fluvoxamine augmentation to clozapine in treatment-resistant psychosis","volume":"41","author":"Leising","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.encep.2019.02.002","article-title":"Case report: pharmacokinetic interaction between clozapine and mirtazapine","volume":"45","author":"Lo Presti","year":"2019","journal-title":"Encephale"},{"key":"10.1016\/j.schres.2023.10.003_bb0200","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","article-title":"Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances","volume":"65","author":"Lu","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2017.06.030","article-title":"Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0210","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/000486700282","article-title":"Neutropenia due to nefazodone, interaction or coincidence?","volume":"34","author":"MacDonald","year":"2000","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0215","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/JCP.0000000000001376","article-title":"A case report of clozapine-associated stuttering and amisulpride-associated stuttering and seizure in an adult on concurrent fluoxetine therapy","volume":"41","author":"Mathur","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0220","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/pgs-2022-0007","article-title":"Evidence of pharmacogenetics-based fluvoxamine use as an add-on to clozapine treatment in psychiatry","volume":"23","author":"Moss\u00e9","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.schres.2023.10.003_bb0225","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1517\/14656566.2014.956082","article-title":"Augmentation strategies in partial responder and\/or treatment-resistant schizophrenia patients treated with clozapine","volume":"15","author":"Muscatello","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.schres.2023.10.003_bb0230","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2023.10.003_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0447.2012.01854.x","article-title":"Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the \u2018real world\u2019","volume":"126","author":"Pai","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.10.003_bb0240","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4088\/JCP.v60n1203","article-title":"The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation","volume":"60","author":"Pallanti","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.schres.2005.07.016","article-title":"Acute effects of clozapine-fluvoxamine combination","volume":"79","author":"Peritogiannis","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4088\/PCC.08l00661","article-title":"Partial seizures with secondary generalization while on treatment with clozapine and sertraline: a case report","volume":"11","author":"Phutane","year":"2009","journal-title":"Prim. Care Companion. J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-199704000-00012","article-title":"Interaction of sertraline with clozapine","volume":"17","author":"Pinninti","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0260","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00213-015-4161-1","article-title":"The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review","volume":"233","author":"Polcwiartek","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2023.10.003_bb0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2011.08.005","article-title":"Clozapine resistance: augmentation strategies","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0270","first-page":"84","article-title":"Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia","volume":"43","author":"Purdon","year":"1998","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0275","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","author":"Reeves","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0280","article-title":"A brief history of clozapine in China with a look forward","author":"Ruan","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"Salahudeen","year":"2015","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.schres.2023.10.003_bb0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2004.03.011","article-title":"Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder symptoms? A systematic review","volume":"82","author":"Sareen","year":"2004","journal-title":"J. Affect Dis."},{"key":"10.1016\/j.schres.2023.10.003_bb0295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0897190020904280","article-title":"Bupropion with clozapine: case reports of seizure after coadministration","volume":"34","author":"Schmitz","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.schres.2023.10.003_bb0300","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22ac14500","article-title":"Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s)","volume":"83","author":"Schoretsanitis","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0305","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.schres.2018.05.034","article-title":"Navigating the co-prescription of clozapine and fluvoxamine","volume":"202","author":"Shymko","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0310","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1527-3458.2001.tb00200.x","article-title":"Fluvoxamine as an adjunctive agent in schizophrenia","volume":"7","author":"Silver","year":"2001","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.schres.2023.10.003_bb0315","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0004867418772351","article-title":"Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis","volume":"52","author":"Siskind","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0320","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.10.003_bb0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.schres.2023.10.003_bb0330","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.schres.2023.10.003_bb0335","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.schres.2023.10.003_bb0340","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-199733060-00004","article-title":"Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence","volume":"33","author":"Sproule","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2023.10.003_bb0345","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.pnpbp.2009.09.014","article-title":"Clozapine-induced sialorrhea alleviated by bupropion\u2014a case report","volume":"33","author":"Stern","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0350","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1345\/aph.1L066","article-title":"Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome","volume":"42","author":"Stevens","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2023.10.003_bb0355","article-title":"Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: a systematic review","author":"Tanzer","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2023.10.003_bb0360","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00004850-199905030-00007","article-title":"The effect of nefazodone on clozapine plasma concentrations","volume":"14","author":"Taylor","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0365","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0370","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0375","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0034-1385930","article-title":"Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/acps.12344","article-title":"Clozapine use pattern in persons with and without treatment for Parkinson\u2019s disease in real-world conditions: a naturalistic study in a community-based sample","volume":"130","author":"Verdoux","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.10.003_bb0385","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","article-title":"Prescriber and institutional barriers and facilitators of clozapine use: a systematic review","volume":"201","author":"Verdoux","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0390","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/acps.13020","article-title":"Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample","volume":"139","author":"Verdoux","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.10.003_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2019.07.040","article-title":"Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review","volume":"211","author":"Verdoux","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0400","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1017\/S0033291720001403","article-title":"Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers","volume":"51","author":"Verdoux","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2023.10.003_bb0405","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00406-020-01207-x","article-title":"Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers","volume":"271","author":"Verdoux","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2023.10.003_bb0410","article-title":"Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations","author":"Verdoux","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.003_bb0415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0269881118822171","article-title":"Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance","volume":"33","author":"Wagner","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.003_bb0420","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","article-title":"Clozapine combination and augmentation strategies in patients with schizophrenia\u2014recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working group","volume":"46","author":"Wagner","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.10.003_bb0430","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/0004867418812681","article-title":"A case of recurrent seizures: drug-drug interaction between low-dose clozapine and extended-release bupropion","volume":"53","author":"Yang","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.003_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103375","article-title":"Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment","volume":"79","author":"Yeh","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.schres.2023.10.003_bb0440","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacol. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T11:50:35Z","timestamp":1718106635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423003560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":87,"alternative-id":["S0920996423003560"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}